Kura Oncology WKN: A143UH ISIN: US50127T1097 Kürzel: KUR Branche: Chemie, Pharma, Biotechnologie
Marktkapitalisierung
1,3 Mrd. USD
KGV
-8,07
Ergebnis je Aktie
-2,32 USD
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
Robo1976,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 30. Jan 13:18 Uhr
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
Solix,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 30. Jan 13:16 Uhr
🎈
O
Overburner,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 24.01.2024 16:52 Uhr
So machen Kapitalerhöhungen Spass... https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-oversubscribed-150-million-private
abeni,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 03.11.2022 12:04 Uhr
$KURA Announces Financing Transactions with $BMY and Hercules Capital, Providing Access to up to $150M.
$25M equity investment from $BMY at $18.25/share
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 05.08.2021 22:31 Uhr
Kura Oncology Reports Second Quarter 2021 Financial Results
https://www.globenewswire.com/news-release/2021/08/05/2276004/35186/en/Kura-Oncology-Reports-Second-Quarter-2021-Financial-Results.html
– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 –
– Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in HNSCC –
– KO-2806 nominated as lead development candidate in next-generation farnesyl transferase inhibitor program –
– $567.5 million in cash, cash equivalents and investments provide runway into 2024 –
...
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 06.07.2021 15:48 Uhr
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
https://www.gurufocus.com/news/1468895/kura-oncology-announces-clinical-collaboration-to-evaluate-tipifarnib-in-combination-with-alpelisib-in-head-and-neck-squamous-cell-carcinoma
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 24.06.2021 14:46 Uhr
Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539
https://www.globenewswire.com/news-release/2021/06/24/2252605/35186/en/Kura-Oncology-Doses-First-Patient-in-Phase-1b-Expansion-Cohorts-with-Menin-Inhibitor-KO-539.html
– Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose –
– At least 12 patients to be enrolled in each of two Phase 1b expansion cohorts: a 200 mg dose cohort and a 600 mg dose cohort –
– Each cohort to be genetically enriched with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients –
– Company anticipates that patient data from the recommended Phase 2 dose cohort will be included as part of the registration-directed portion of the trial –
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 22.03.2021 21:35 Uhr
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
https://www.globenewswire.com/news-release/2021/03/22/2197210/0/en/Kura-Oncology-Announces-Publication-of-Tipifarnib-Phase-2-Data-in-Journal-of-Clinical-Oncology.html
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC –
– Statistically significant improvement in median PFS compared with median PFS of 3.6 months on last prior therapy (p=0.0012) –
– Safety profile consistent with previously published data for tipifarnib –
– Results support continuation of AIM-HN registration-directed trial in HRAS mutant HNSCC –
...
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 24.02.2021 13:31 Uhr
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
https://www.globenewswire.com/news-release/2021/02/24/2181292/0/en/Kura-Oncology-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html
- Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations –
– KO-539 continues to demonstrate a wide therapeutic window in dose escalation; protocol amendment to include genetically enriched Phase 1 expansion cohorts –
– Tipifarnib receives Breakthrough Therapy Designation from FDA –
– $633.3 million in cash, cash equivalents and investments provide runway into 2024
– Management to host webcast and conference call today at 8:00 a.m. ET –
....
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 24.02.2021 13:21 Uhr
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
http://www.globenewswire.com/news-release/2021/02/24/2181242/0/en/Kura-Oncology-Receives-FDA-Breakthrough-Therapy-Designation-for-Tipifarnib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html
...today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy. Tipifarnib is currently being evaluated in an ongoing registration-directed clinical trial (AIM-HN) in this indication of high unmet need. ...
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 08.01.2021 22:39 Uhr
Kura teams up with Illumina for a companion diagnostic for lead therapy
https://seekingalpha.com/news/3650072-kura-teams-up-illumina-for-companion-diagnostic-for-lead-therapy
In a regulatory filing, Kura Oncology (NASDAQ:KURA) announces that on January 04, it entered into a collaboration agreement, with Illumina (NASDAQ:ILMN) for a companion diagnostic test for use with the company’s lead product candidate, tipifarnib.
The agreement tided to a project schedule will require Illumina to develop and commercialize an assay as a companion diagnostic test for use with tipifarnib to identify head and neck squamous cell carcinoma (‘HNSCC”) patients with an HRAS mutation.
The collaboration covers the United States, the United Kingdom, major European markets, and other countries as mutually agreed by the two parties.
Currently, Kura is advancing a global, multi-center, open-label, non-comparative registration-directed clinical trial of tipifarnib in HRAS mutant HNSCC.
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 11.12.2020 22:33 Uhr
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
https://www.globenewswire.com/news-release/2020/12/11/2144046/0/en/Kura-Oncology-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-Option-to-Purchase-Additional-Shares.html
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 10.12.2020 19:50 Uhr
https://seekingalpha.com/article/4394095-kura-oncology-advanced-precision-medicine-opportunity-excites-not-without-risks
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 09.12.2020 11:17 Uhr
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
https://www.globenewswire.com/news-release/2020/12/09/2141845/0/en/Kura-Oncology-Announces-Pricing-of-300-Million-Public-Offering-of-Common-Stock.html
...at a price to the public of $37.00 per share.
Summer.76,
KURA ONCOLOGY DL-,…
Hauptdiskussion, 08.12.2020 6:44 Uhr
Kura Oncology Announces Commencement of Public Offering of Common Stock
https://www.globenewswire.com/news-release/2020/12/07/2140893/0/en/Kura-Oncology-Announces-Commencement-of-Public-Offering-of-Common-Stock.html
|
Themen zum Wert | ||
---|---|---|---|
1 | KURA ONCOLOGY DL-,0001 Hauptdiskussion |
Anzeige
Kursdetails
Geld (bid) | 19,62 (2.300) |
---|---|
Brief (ask/offer) | 19,64 (200) |
Spread | 0,10 |
Geh. Stück | 494 Tsd. |
Eröffnung | 19,20 |
Vortag | 19,00 |
Tageshoch | 19,71 |
Tagestief | 18,96 |
52W Hoch | 24,06 |
52W Tief | 7,42 |
Tagesvolumen
in USD gehandelt | 1,1 Mio. Stk |
---|---|
in EUR gehandelt | 0 Stk |
Gesamt | 1,1 Mio. Stk |
Partner-News
AnzeigeGestern 18:01 Uhr • Partner • Societe Generale
Gestern 16:45 Uhr • Partner • Societe Generale
Gestern 16:07 Uhr • Partner • Societe Generale
Gestern 15:24 Uhr • Partner • Societe Generale
Gestern 15:20 Uhr • Partner • onemarkets Blog
Aktien-News
Gestern 22:28 Uhr • Artikel • dpa-AFX
Gestern 22:15 Uhr • Artikel • dpa-AFX
Gestern 19:43 Uhr • Artikel • BörsenNEWS.de
Gestern 19:34 Uhr • Artikel • BörsenNEWS.de
Gestern 19:31 Uhr • Partner • shareribs
Geld/Brief Kurse
Neu ladenBörse | Geld | Vol. | Brief | Vol. | Zeit | Vol. ges. | Kurs |
---|---|---|---|---|---|---|---|
NYS | 19,49 | 700 Stk | 19,65 | 100 Stk | 1714176000 02:00 | 23.296 Stk | 19,65 USD |
L&S Exchange | 18,36 | 399 Stk | 18,75 | 399 Stk | 1714165238 26. Apr | 18,56 EUR | |
AMEX | 1714176000 02:00 | 19,48 USD | |||||
UTP Consolidated | 19,62 | 2.300 Stk | 19,64 | 600 Stk | 1714176000 02:00 | 577 Tsd. Stk | 19,65 USD |
Baader Bank | 18,26 | 18,44 | 1714161600 26. Apr | 18,35 EUR | |||
Frankfurt | 18,28 | 500 Stk | 18,47 | 500 Stk | 1714111294 26. Apr | 17,63 EUR | |
Tradegate | 17,98 | 166 Stk | 18,72 | 160 Stk | 1714163204 26. Apr | 18,35 EUR | |
Lang & Schwarz | 18,36 | 399 Stk | 18,75 | 399 Stk | 1714165236 26. Apr | 18,56 EUR | |
TTMzero RT | 1714161602 26. Apr | 18,35 EUR | |||||
Berlin | 18,15 | 1.470 Stk | 18,55 | 1.470 Stk | 1714154900 26. Apr | 18,32 EUR | |
Düsseldorf | 18,16 | 720 Stk | 18,56 | 720 Stk | 1714152664 26. Apr | 17,95 EUR | |
Stuttgart | 18,17 | 1.000 Stk | 18,55 | 1.000 Stk | 1714120364 26. Apr | 17,55 EUR | |
Gettex | 18,25 | 500 Stk | 18,47 | 500 Stk | 1714160651 26. Apr | 18,21 EUR | |
Quotrix Düsseldorf | 18,17 | 720 Stk | 18,55 | 720 Stk | 1714161600 26. Apr | 18,36 EUR | |
Nasdaq | 19,62 | 2.300 Stk | 19,64 | 200 Stk | 1714176000 02:00 | 494 Tsd. Stk | 19,65 USD | ges. 1.094.542 Stk |
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR |
---|
1,3 Mrd. |
Anzahl der Aktien |
68,4 Mio. |
Termine
08.05.2024 | Quartalsmitteilung |
---|---|
01.08.2024 | Quartalsmitteilung |
31.10.2024 | Quartalsmitteilung |
02/25 | Quartalsmitteilung |
Aktionärsstruktur %
Freefloat | 0,00 |
0,00 |
Grundlegende Daten zur KURA ONCOLOGY DL-,0001 Aktie
Finanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
---|---|---|---|---|---|---|---|
Ergebnis je Aktie (bereinigt) | -1,52 | -1,95 | -2,01 | -1,97 | -2,32 | - | - |
Cashflow | -69,8 Mio. | -0,1 Mrd. | -0,1 Mrd. | -0,1 Mrd. | - | - | - |
Eigenkapitalquote | - | - | - | 88,49 % | - | - | - |
Verschuldungsgrad | - | - | - | 13,00 | - | - | - |
EBIT | -92,1 Mio. | -0,1 Mrd. | -0,1 Mrd. | -0,2 Mrd. | - | - | - |
Fundamentaldaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
KCV | -27,45 | -8,92 | -7,66 | -8,93 | - | - | - |
Kurs-Gewinn-Verhältnis (KGV) | -21,49 | -7,18 | -6,17 | -7,30 | -8,07 | - | - |
Bilanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
Ergebnis vor Steuern | -89,6 Mio. | -0,1 Mrd. | -0,1 Mrd. | -0,2 Mrd. | - | - | - |
Steuern | -0,2 Mio. | -0,6 Mio. | 229 Tsd. | - | - | - | - |